This map shows the geographic impact of M Karon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Karon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Karon more than expected).
This network shows the impact of papers produced by M Karon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Karon. The network helps show where M Karon may publish in the future.
Co-authorship network of co-authors of M Karon
This figure shows the co-authorship network connecting the top 25 collaborators of M Karon.
A scholar is included among the top collaborators of M Karon based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with M Karon. M Karon is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Leikin, Sanford, Vincent Albo, Harland N. Sather, et al.. (1980). Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children's Cancer Study Group Report.. PubMed. 64(2-3). 381–92.42 indexed citations
5.
Chard, Ronald L., et al.. (1979). Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia.. PubMed. 1(1). 9–13.78 indexed citations
6.
Karon, M, et al.. (1976). Detection of bacterial endotoxin in antitumor agents.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 60(1). 9–15.2 indexed citations
7.
Karon, M, et al.. (1976). Dibromodulcitol (NSC-104800) compared with cyclophosphamide (NSC-26271) as remission maintenance therapy in previously treated children with acute lymphoblastic leukemia or acute undifferentiated leukemia: possible effectiveness in reducing the incidence of central nervous system leukemia.. PubMed. 59(5). 989–94.4 indexed citations
Ortega, José Antonio, J Z Finklestein, Inta J. Ertel, Danielle Hammond, & M Karon. (1972). Effective combination treatment of advanced acute lymphocytic leukemia with cytosine arabinoside (NSC-63878) and L-asparaginase (NSC-109229).. PubMed. 56(3). 363–8.5 indexed citations
Scher, Jordan M., et al.. (1970). Pharmacologic studies of tritiated cytosine arabinoside (NSC-63878) in children.. PubMed. 54(1). 35–9.11 indexed citations
13.
Karon, M. (1968). Effectiveness of vincristine (NSC-67574) against refractory leukemia in children.. PubMed. 52(4). 473–6.2 indexed citations
14.
Karon, M, et al.. (1966). Studies of the kinetics of alpha and beta hemoglobin chain synthesis.. PubMed. 67(2). 246–54.15 indexed citations
15.
Henry, Patrick H., et al.. (1966). Synthesis of acid-soluble proteins by the lymphocytes of chronic lymphocytic leukemia.. PubMed. 67(5). 757–63.3 indexed citations
16.
Ra, Malmgren, et al.. (1965). Immunofluorescence studies in human leukemia.. PubMed. 4. 187–96.1 indexed citations
Freireich, E. J., E Frei, & M Karon. (1962). Methylglyoxal bis (guanylhydrazone): a new agent active against acute myelocytic leukemia.. PubMed. 16. 183–6.43 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.